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Objectives: Skin fibrosis is the hallmark of systemic sclerosis (SSc) a rare intractable
disease with unmet medical need. We previously reported the anti-fibrotic potential of
mesenchymal stem cells (MSCs) in a murine model of SSc. This model, based on daily
intra-dermal injections of hypochlorite (HOCl) during 6 weeks, is an inducible model
of the disease. Herein, we aimed at characterizing the development of skin fibrosis in
HOCl-induced SSc (HOCl-SSc), and evaluating the impact of MSC infusion during the
fibrogenesis process.
Methods: After HOCl-SSc induction in BALB/c mice, clinical, histological and biological
parameters were measured after 3 weeks (d21) and 6 weeks (d42) of HOCl challenge,
and 3 weeks after HOCl discontinuation (d63). Treated-mice received infusions of 2.5 ×
105 MSCs 3 weeks before sacrifice (d0, d21, d42).
Results: HOCl injections induced a two-step process of fibrosis development:
first, an ‘early inflammatory phase’, characterized at d21 by highly proliferative
infiltrates of myofibroblasts, T-lymphocytes and macrophages. Second, a phase
of ‘established matrix fibrosis’, characterized at d42 by less inflammation, but
strong collagen deposition and followed by a third phase of ‘spontaneous tissue
remodeling’ after HOCl discontinuation. This phase was characterized by partial fibrosis
receding, due to enhanced MMP1/TIMP1 balance. MSC treatment reduced skin
thickness in the three phases of fibrogenesis, exerting more specialized mechanisms:
immunosuppression, abrogation of myofibroblast activation, or further enhancing tissue
remodeling, depending on the injection time-point.
Conclusion: HOCl-SSc mimics three fibrotic phenotypes of scleroderma, all positively
impacted by MSC therapy, demonstrating the great plasticity of MSC, a promising cure
for SSc.
Keywords: mesenchymal stem cells, systemic sclerosis, fibrosis, hypochlorite, oxidative stress, scleroderma, cell
therapy, autoimmunity
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INTRODUCTION
Skin fibrosis is the hallmark of systemic sclerosis (scleroderma,
SSc), a rare intractable autoimmune disorder with highmorbidity
and mortality due to multi-organ involvement (1). Although
precise etiology for SSc remains unknown, fibrosis development
in the disease may originate from a complex interplay between
environmental and intrinsic triggers–including oxidative stress-
leading to tissue damage, immune response, endothelial cell
and myofibroblast activation. The latter results in fibroblast
proliferation and extracellular matrix (ECM) production (2–4).
However, fibrogenesis is a dynamic process, with counteracting
mechanisms involved to dampen immune activation or up-
regulate tissue remodeling. So, different stages of tissue fibrosis
may be observed, with variable participation of immune cell
activation, angiogenesis or ECM synthesis by fibroblasts. Thus,
targeting fibrosis in SSc may be challenged by the complexity
of this multistage process, as well as the unpredictability of
clinical evolution. Studies are still on going to help defining more
precisely the clinical and biological status of SSc patients, hence
refining therapy (5, 6).
Among new potential approaches for treating SSc,
mesenchymal stem cells (MSCs)-based therapy stands as a
promising lead (7). Indeed, these mesodermal multipotent
progenitors can be easily isolated and expanded from virtually all
tissues, and display both immunomodulatory and anti-fibrotic
properties when infused (8). We recently demonstrated the
feasibility and the therapeutic benefits of an approach based
on MSCs in a preclinical murine model for SSc (9, 10). In this
model, fibrosis is induced by repeated exposure to hypochlorite
(HOCl), an oxidative agent administered by daily intra-dermal
injections during 6 weeks. This model, mimicking early diffuse
cutaneous SSc, is particularly useful to evaluate new therapeutic
approaches. However, we still lack data on the development
and the spontaneous evolution of fibrosis in HOCl-induced SSc
(HOCl-SSc), as well as the impact of MSCs-based therapy along
the process.
In this study, we first precisely characterized the fibrotic
process induced by HOCl injections, as well as the evolution
of fibrosis after discontinuation of HOCl challenge. Doing
so, we further investigated the impact of MSC infusion, at
each stage of the process, on skin fibrosis, inflammation and
remodeling.
MATERIALS AND METHODS
Isolation and Culture of Mesenchymal
Stem Cells
MSCs from BALB/c mice were isolated from bone marrow (BM).
BM was flushed out from long bones and the cell suspension
was plated in DMEM supplemented with 10% fetal bovine serum
(FBS) (PAA Laboratories GmbH, Austria), 2mM glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin (Lonza, France).
Cells were passaged till obtaining homogeneity for mesenchymal
marker expression and lack of hematopoietic markers as analyzed
by flow cytometry. They were used between passages 10 and 15.
Flow Cytometry Analysis
Cells were harvested by treatment with 0.05% trypsin and
0.53mM EDTA, and resuspended in PBS containing 0.1% BSA
and 0.01% sodium azide. Cells were incubated on ice with
conjugated antibodies against CD11b, CD44, CD45, CD73, and
Sca1 (BD Pharmingen, France) or conjugated isotypic controls.
Samples were analyzed on the FACS Canto II and analysis
performed using the BD FACSdiva software (BD Pharmingen).
Differentiation of MSCs
Differentiation of MSCs was induced as reported elsewhere (11).
In brief, for adipogenesis, MSCs were plated at 104 cells/cm2 in
inductive medium and adipocytes characterized by presence of
lipid droplets as visualized by Oil red O staining and expression
of specific markers by RT-qPCR. Chondrogenic differentiation
was induced by culture in micropellet and chondrogenesis was
assessed by RT-qPCR. Osteogenesis was induced by culture at
low density in osteogenic medium. Differentiation was assessed
by RT-qPCR quantification of osteoblast markers and ECM
mineralization visualized after staining with a 2% Alizarin Red
S solution.
T-Cell Proliferation Assay
For T-cell proliferative experiments, 105 splenocytes were
stimulated with 1µg/ml concanavalin A (conA; Sigma-Aldrich,
France) in presence of different ratios of MSCs as already
reported (11). After 3 days, cell proliferation was measured using
the CellTiter-Glo
TM
luminescent cell viability assay (Promega,
France).
HOCl Preparation
HOCl was generated extemporaneously by adding NaClO (9.6%
as active chlorine) to KH2PO4 solution (100mM, pH: 6.2),
usually using a 1:100 ratio. The right amount of NaClO was
adjusted to obtain the desired HOCl concentration, defined
by the absorbance of the mixture at 292 nm (optical density
between 0.7 and 0.9 read on a Nanodrop spectrophotometer,
Thermoscientific). Stock solutions were stored at 4◦C in the dark
and NaClO was replaced every 3 weeks.
Experimental Design and Animals
Six-week-old female BALB/c mice purchased from Janvier were
housed and cared for according to the Laboratory Animal
Care guidelines. Approval was obtained from the Regional
Ethics Committee on Animal Experimentation before initiation
of the study (approval APAFIS#5351-2016050919079187). All
experiments were performed after final approval given by the
French Ministry for Education, Higher Education and Research.
Mice had their backs shaved the day before disease induction.
Skin thickness was assessed with a caliper before disease
induction and every week during the whole experiment by a
blinded experimenter. As previously described, a total amount
of 300 µl of freshly prepared HOCl was injected in two sites
into the backs of the mice with a 29G needle, 5 days a week
for 6–9 weeks [d0 to d42 or day 63; (12)]. Control mice
received PBS in the same conditions. MSCs-treated SSc-HOCl
mice received an infusion of MSCs (2.5 × 105 cells in 100
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µl PBS), in the tail vein of the mice at indicated time points
(d0, d21, d42). Groups of 7 to 10 mice were made for each
condition (PBS-, HOCl- and MSCs-treated HOCl-mice). Three
weeks after MSCs infusion, and after a 2-day recovery time
without HOCl injections, animals were sacrificed, at indicated
time points (d21, d42, or d63). Skin biopsies (6mm punches)
were taken on the backs of mice. Samples were stored at −80◦C
for RT-qPCR, ELISA and collagen content determination or
fixed in 4% formaldehyde for histopathological analysis. Overall
experimental scheme is shown in Figure 1, and representative
pictures of mice during experimental procedure are shown in
Supplementary Figure 1.
Histopathology
Samples were embedded in paraffin and 5µm thick sections
were stained with Masson trichrome or immunostained with
antibodies for α-sma (ab5694, Abcam, 1/100) TGFβ (ab66043,
Abcam, 1 /100), Ki67 (SP6, VP-RM04, Vector laboratories,
1/200), CD3-epsilon (M-20, sc−1127, Santa Cruz Biotechnology,
1/250), F4/80 (MF4800, Invitrogen, 1/50), Pax5 (C-20, sc−1974,
Santa Cruz Biotechnology, 1/250). Histological slides were
scanned using Nanozoomer (Hamamatsu) or Pannoramic 250
Flash II (3DHistech) for immunofluorescence. Quantification
of immunostaining was made using Definiens Tissue Studio
software.
FIGURE 1 | Development of skin fibrosis in HOCl-mice: experimental scheme.
To induce systemic sclerosis, BALB/c mice underwent 6 weeks of daily HOCl
intradermal injections, while control mice received PBS injections. Skin
thickness was measured weekly during the experiment. After d42 (6 weeks),
HOCl injections were abrogated, and groups of mice were kept in order to
investigate skin thickness evolution till d63. Groups of mice were sacrificed at
indicated time points (d21, d42, d63).
RT-qPCR Analysis
Samples (cells or skin biopsies) were crushed in RLT-buffer and
total RNA was extracted using the RNeasy mini kit and Qiacube
robotic workstation (Qiagen, France). 1 µg RNA was reverse
transcribed using the Moloney Murine Leukemia Virus Reverse
Transcriptase (M-MLV RT, Invitrogen, France). qPCR was
performed on 20 ng cDNA using LightCycler 480 SYBRGreen
I Master mix and real-time PCR instrument (Roche Applied
Science, France). The following conditions were used: 95◦C for
5min; 40 cycles at 95◦C for 15 s; 64◦C for 10 s and 72◦C for
20 s in a LightCycler 480 system (Roche diagnostics, France)
and analyzed with the dedicated software. Primers were designed
using the web-based applications Primer3 and BLAST (Table 1).
Samples were normalized to mRNA expression of TATA binding
protein (Tbp) gene for tissue samples or GAPDH for MSCs,
and results were provided either as relative expression to the
housekeeping gene using the formula 2−1Ct or as fold change
using the formula 2−11Ct.
Collagen Content in Skin
Collagen content assay was based on the quantitative dye-
binding Sircol method (Biocolor, Ireland). Skin biopsies were
suspended in 2ml of a 0.5M acetic acid—pepsin (2.5 mg/ml)
solution and dissociated using UltraTurrax (vWR, France).
Collagen extraction was performed overnight at 4◦C under
stirring. Suspension was then centrifuged at 12,000 g for 10min
and 20 µl of each sample were added to 1ml of Syrius red
reagent. Tubes were rocked at room temperature for 30min
and centrifuged at 12,000 g for 10min. The supernatants were
discarded and tubes washed with 750 µl of ice-cold salt acid.
After another 12,000 g centrifugation for 10min, the collagen-dye
pellets were suspended in 1ml of 0.5M NaOH. Optical Density
(OD) was read at 555 nm on a microplate reader (Varioskan
Flash, Thermo scientific) vs. a standard range of bovine collagen
type I concentrations (supplied as a sterile solution in 0.5M acetic
acid). Results were expressed as collagen content in µg/mm2 of
skin.
Anti-topoisomerase 1 Antibody Elisa
Anti-topoisomerase 1 or anti-scl-70 antibodies were detected
using scl-70 Ig ELISA kit (Abnova, Taiwan). In brief, 200 µl of
1:5 diluted sera were dispensed into scl-70 pre-coated wells and
incubated at room temperature for 90min. Goat total anti mouse
IgG antibody, HRP conjugate (BD Biosciences, France), diluted
1:1,000 was then incubated for 60min at room temperature. TMB
substrate was incubated for 5min and stopped with an equivalent
amount of sulfuric acid. Absorbance was read at 450 nm under
Varioskan Flash and results expressed as arbitrary unit (AU)
for optical density (OD).
Statistical Analysis
All quantitative data were expressed as mean +/- SEM.
Gaussian distribution of values was tested using the Shapiro-
Wilk normality test. Data were then compared using Mann-
Whitney’s test for nonparametric values or Student’s t-test for
parametric values. When analysis included more than two
groups, one-way ANOVA was used. All statistical analyses
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TABLE 1 | List of primers designed and used in RT-qPCR experiments.
Gene abbreviation Forward primer sequence (5′-3′) Reverse primer sequence (5′-3′)
Ap GTGGTGGACGGTGAACGGGA TCCACCGTGGGTCTCATGGC
αSma AAGGCCAACCGGGAGAAAAT AGCCAAGTCCAGACGCATGA
Col1 TGTTCAGCTTTGTGGACCTC TCAAGCATACCTCGGGTTTC
Col2B CTGGTGCTGCTGACGCT GCCCTAATTTTCGGGCAT
Col3 CGGTGAACGGGGCGAAGCTGGTT GACCCCTTTCTCCTGCGGCTCCT
Col10 TGCTGCCTCAAATACCCTTT CAGGAATGCCTTGTTCTCCT
Fabp4 CGTAAATGGGGATTTGGTCA TCGACTTTCCATCCCACTTC
Gapdh GGTGCTGAGTATGTCGTGGA GTGGTTCACACCCATCACAA
Il1b TTTGACAGTGATGAGAATGACCTGTTC TCATCAGGACAGCCCAGGTCAAAG
Il6 TGGGACTGATGCTGGTGACA TTCCACGATTTCCCAGAGAACA
Il10 GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT
Lpl TTTGGCTCCAGAGTTTGACC GTCTTGCTGCTGTGGTTGAA
Mmp1 TTCAAAGGCAGCAAAGTATGGGCT CCAGTCTCTTCTTCACAAACAGCAGCA
Oc GCGCTCTGTCTCTCTGACCT GCCGGAGTCTGTTCACTACC
Pparγ AAGAGCTGACCCAATGGTTG GGATCCGGCAGTTAAGATCA
Runx2 ACAGTCCCAACTTCCTGTGC ACGGTAACCACAGTCCCATC
Sox9 AGGAAGCTGGCAGACCAGTA CTCCTCCACGAAGGGTCTCT
Tbp GGGAGAATCATGGACCAGAA CCGTAAGGCATCATTGGACT
Tgfβ1 TGCGCTTGCAGAGATTAAAA CTGCCGTACAACTCCAGTGA
Timp1 CTCCGCCCTTCGCATGGACATT GGGGGCCATCATGGTATCTGCTCT
Tnfα AGCCCACGTCGTAGCAAACCA TGTCTTTGAGATCCATGCCGTTGGC
Ap, alkaline phosphatase; aSma, alpha, smooth muscular actin; Col, collagen; Fabp, fatty acid binding protein; Gapdh, glyceraldehyde-3-phosphate deshydrogenase; Hmox, heme
oxygenase; Il, interleukin; Lpl, lipoprotein lipase; Mmp, metalloprotease; Oc, osteocalcin; Ppar, peroxisome proliferator-activated receptor; Runx, Runt related transcription factor; Sox,
SRY (sex determining region Y)-related HMG (high mobility group)-box gene; Tbp, TATA binding protein; Timp, tissue inhibitor of metalloproteinase; Tnf, tumor necrosis factor.
were performed using Prism 6 GraphPad software for Mac
OS (California, United States). A P < 0.05 was considered
significant.
RESULTS
Induction of Skin Fibrosis Under HOCl
Challenge Is a Two-Step Process With
Early Proliferative and Inflammatory Stage
and Late Constitution of ECM Deposition
As previously shown, the induction of skin fibrosis by daily
HOCl injections was clinically characterized by progressive
thickening of skin from d7 to d42 when compared with
control PBS-mice (Figure 2A and Supplementary Figure 1).
At d42, histology disclosed strong collagen deposition in
skin from HOCl-mice compared with PBS mice, as shown
by sirius red coloration (Figure 2B). Histological examination
from sequential sacrifices revealed a discontinued process with
two main stages. First, in the third week of experiment
(d14–d21), we observed transparietal polymorphous cellular
infiltrates; second, in the last week of experiment (d35–
d42), these cellular infiltrates were gradually replaced by
ECM deposition, resulting in disorganization of dermis and
complete loss of hypodermic adipose tissue (Figure 2C). During
the process, we noted a strong and steady expression of
myofibroblastic markers αSma and Tgfβ1 in dermis from
SSc mice, with no obvious difference between d21 and d42
(Figure 2D).
While comparing these two main time points (i.e., d21 and
d42), we observed a higher number of proliferative cells in skin
tissues at d21 compared with d42, as shown by Ki67 staining
(Figures 3A,B). Looking at cytokine mRNA expression within
the tissue, we noted a stronger expression of pro-inflammatory
cytokines Il1β and Tnfα at d21 compared with d42, together
with a lower expression of the anti-inflammatory cytokine
Il10 (Figure 3C). We therefore focused on d21, and further
characterized these cellular infiltrates by immunostaining. We
observed high number of CD3+ T-lymphocytes, of F4/80+
macrophages, but no Pax5+ B cells (Figure 4). Of note,
we also noticed some cells co-expressing CD3 and Ki67
(data not shown).
Altogether, the analysis of skin fibrosis kinetics during
the induction of HOCl-SSc revealed a two-step process,
with an early cellular phase made of highly proliferative T-
lymphocytes, macrophages and myofibroblasts, culminating at
d21, and a late evolution toward paucicellular matricial fibrosis
mainly characterized by ECM deposition at d42. Conversely,
as previously reported, lung fibrosis development in this
model is a continuous and progressive process, leading to
tissue fibrosis at the end of the 6-wk experiment [(9) and
Supplementary Figure 2]. For these reasons and because skin
fibrosis is the hallmark of SSc, we kept focused on skin fibrosis
development in the present study.
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FIGURE 2 | Development of skin fibrosis in HOCl-mice. (A) Skin thickness from PBS or HOCl-injected mice at different time-points during the induction of HOCl-SSc
(d0 to d42) (N = 8 per group) **P < 0.001, ***P < 0.001. (B) Representative skin sections of PBS and HOCl mice at d42 (original magnification 10x; Sirius Red
staining). (C) Representative skin sections at different time-points during the induction of HOCl-SSc (original magnification 10x; Masson Trichrome staining).
(D) Immunostaining for αSma (in red) and Tgfβ1 (in green) in representative skin sections at d21 and d42.
MSCs-Based Treatment Efficiently
Reduces Inflammation During the First
Stage of Fibrosis Constitution in HOCl-SSc
In a first experiment, we aimed at evaluating the anti-
inflammatory impact of MSCs-based treatment administered
during the first stage of fibrosis induction in the model (d0–
d21). Therefore, we used MSCs isolated from BALB/c mice
in a syngeneic approach. These cells were characterized by
the expression of CD44, CD73, CD29, CD105, CD106, and
stem cell antigen 1 (Sca1), and the absence of expression
of the haematopoietic markers CD45, CD3, CD19, CD31,
CD11b, and HLA-DR by cytometry analysis (Figures 5A,B).
MSCs exerted immunosuppressive properties on the mitogen-
induced proliferation of T-lymphocytes (Figure 5C) and were
able to differentiate into adipocytes expressing lipoprotein
lipase (Lpl), peroxisome proliferator-activated receptor
(Pparγ ), fatty acid binding protein (Fabp4) (Figure 5D),
chondrocytes expressing SRY (sex determining region Y)-related
HMG (high mobility group)-box gene (Sox9), Col2B, Col10
(Figure 5E) and osteoblasts expressing osteocalcin (Oc), alkaline
phosphatase (Ap), Col1, Runt related transcription factor (Runx2;
Figure 5F).
A unique dose of 2.5 × 105 MSCs was administered
intravenously before HOCl induction at d0, and mice were
sacrificed 3 weeks later. A significant reduction of skin thickness
was obtained at d21 in MSCs-treated SSc mice compared
with untreated SSc mice (Figure 6A). Because inflammation
was the highest at d21, we analyzed the effect of MSCs on
inflammatory mediators in skin. MSCs treatment was associated
with a significant decrease of Il1β, Tnfα, Il6, and Il10 expression
compared with untreated SSc mice (Figure 6B). Histological
analysis revealed overall less cellular infiltrates in MSCs-treated
mice, together with less Ki67 staining, strong decrease in CD3
staining and almost abolition of F4/80 staining (Figures 6C,D).
MSC infusion also prevented specific anti-scl70 autoantibody
production as detected in the serum (Supplementary Figure 3).
On the whole, MSCs treatment during the first phase
of HOCl-induced fibrosis prevented skin inflammation
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FIGURE 3 | Cell proliferation and cytokine production in skin during fibrosis
induction in HOCl-mice. (A) Immunostaining for nuclear Ki67 in representative
skin sections at d21 and d42 (top panels: magnification 10x, bottom panels:
top image box, 30x). (B) Percentage of Ki67+ proliferative cells in dermis as
quantified on immunostaining in A using Definiens Tissue Studio software
(n = 3 per group, *P < 0.05, **P < 0.01). (C) mRNA expression of Il1b, Tnfa,
Il6 and Il10 in skin sections from HOCl-SSc mice at d21 and d42. Results are
given as fold-change vs. control PBS-mice normalized at 1. N = 8 per group.
by down-regulating T-cell and macrophage immune
response resulting in reduced cytokine and autoantibody
production.
MSCs Treatment Reduces Myofibroblastic
Activation and Collagen Deposition During
the Second Stage of Fibrosis Constitution
in SSc Mice
We then investigated the effect of a single infusion of
2.5 × 105 MSCs administered at d21 on the second
phase of HOCl-SSc induction (d21–d42). MSCs treatment
completely inhibited skin thickening during the whole
period, resulting in significantly reduced skin thickness at
d42 (Figure 7A and Supplementary Figure 1). At the end
FIGURE 4 | Inflammatory cell infiltrates within dermis during fibrosis induction
in HOCl-mice. Immunostaining for Ki67+ proliferative cells, CD3+
T-lymphocytes, F4/80+ macrophages and Pax5+ B lymphocytes in
representative skin sections at d21 from HOCl mice (original magnification 10x;
enlargement 60x).
of the experiment, MSCs-treated mice exhibited reduced
skin fibrosis characterized by less ECM deposition in
Masson Trichrome staining (Figure 7B) and reduced total
collagen content in skin (Figure 7C), almost reaching the
level of control PBS mice. Immunostaining for α-Sma and
Tgfβ confirmed less myofibroblastic activation in MSCs-
treated mice compared with untreated mice (Figures 7D,F).
Of note, fewer F4/80+ macrophages were also noted in
skin from MSCs-treated mice compared with SSc mice,
whereas no difference could be detected concerning CD3+
lymphocyte infiltrates, since there was almost none in SSc
mice at d42 (Figures 7E,F). However, in this setting, we did
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FIGURE 5 | Phenotypical and functional characterization of BM-derived BALB/c MSCs. (A) Representative graph of flow-cytometry analysis of MSCs stained with
antibodies against CD44, CD73, Sca1, CD45 and CD11b. (B) Percentage of MSCs stained with antibodies against CD29, CD105, CD106, CD3e, CD4, CD19, CD31
and HLA-DR in flow-cytometry analysis. (C) T cell proliferation assay expressed as relative luminescent units (RLU) for splenocytes stimulated with concanavalin A
(ConA) and cultured in presence of MSCs (ratio 1:10 or 1:50; n = 3 per group) *P < 0.05. (D) mRNA expression of Lpl, Pparg and Fabp4 in MSCs, normalized to
Gapdh expression, before (d0) and after (d21) adipogenesis induction. (E) mRNA expression of Col2B, Col10 and Sox9 in MSCs, normalized to Gapdh expression,
before (d0) and after (d21) chondrogenesis induction. (F) mRNA expression of Oc, Ap, Col1 and Runx2 in MSCs, normalized to Gapdh expression, before (d0) and
after (d21) osteogenesis induction. Data are presented as average ± SEM. nd: not detected. Ap, alkaline phosphatase; Col, collagen; Fabp, fatty acid binding protein;
Lpl, lipoprotein lipase; Oc, osteocalcin; Ppar, peroxisome proliferator-activated receptor; Runx, Runt related transcription factor; Sox, SRY (sex determining region
Y)-related HMG (high mobility group)-box gene.
not observe a reduction of anti-scl70 antibody production
(Supplementary Figure 3).
MSCs Treatment After HOCl
Discontinuation Activates Tissue
Remodeling Toward Fibrosis Clearance
In a last experiment, we aimed at investigating both the
evolution of HOCl-SSc after HOCl discontinuation and the
effect of MSCs treatment in this condition. Therefore, we
administered a single infusion of 2.5 × 105 MSCs at d42,
stopped HOCl injections and sacrificed the mice 3 weeks
later (d63). We first observed a spontaneous decrease in
skin thickness in untreated HOCl-induced mice, significant in
the last week of experiment (Figure 8A). MSCs-treated mice
exhibited an earlier and stronger decrease in skin thickness
compared with untreated HOCl-induced mice, significant in
the last 2 weeks (Figure 8A). Histological analysis confirmed
the strong anti-fibrotic effect of MSCs treatment, with an
almost normal aspect of skin compared with untreated HOCl-
induced mice (Figure 8B). Immunostaining for α-SMA and
TGF-β corroborated these observations (Figures 8C,E), while
mRNA expression for the main fibrotic markers confirmed a
significantly reduced expression of Col1, Col3, Tgfβ1, and α-
Sma in MSCs-treated mice compared with untreated HOCl-
induced mice (Figure 8F). Notably, levels of these four markers
were found below the levels of control PBS-mice. Interestingly,
untreated HOCl-induced mice also exhibited lower levels of
α-Sma in comparison with control PBS mice. Concerning
tissue inflammation, we noted residual F4/80 macrophage
infiltrates in SSc mice, which was reduced in MSCs-treated
mice (Figures 8D,E). In MSCs-treated mice we also observed a
reduced expression of Il1β, and Tnfα, while Il6 was increased
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FIGURE 6 | Anti-inflammatory effects of MSC treatment during fibrosis induction in SSc mice at day 21. (A) Skin thickness measured from d0 to d21 in control PBS
mice, non-treated SSc mice and SSc mice treated with 2.5 × 105 MSCs at d0 (MSC0). (B) mRNA expression of IL1b, TNF-a, IL-6 and IL-10 in skin at d21. Results
are given as fold-change vs. control PBS-mice normalized to 1. (C) Nuclear immunostaining for proliferative cells using Ki67 (top panels, in green), CD3+
T-lymphocytes (middle panels, in red), and F4/80+ macrophages (bottom panels, in green), in representative skin sections at d21 from HOCl-SSc mice and
MSCs-treated HOCl-SSc mice. Left: original magnification 10x; middle: part of left image 40x. (D) Quantification of immunostainings in C using Definiens Tissue
Studio IF software (top: percentage of Ki67+ nuclei among all nuclei observed; middle and bottom: absolute number of CD3+ or F4/80+ cells; n = 4). *P < 0.05,
**P < 0.01, ***P < 0.001, data are presented as mean ± SEM. N = 8 for HOCl-mice, N = 7 for MSCs-treated mice.
and Il10 remained unaffected (Figure 8F). Looking for changes
in tissue remodeling, we noted a positive effect of MSCs
treatment, associated with significant increased expression of
metalloproteinase 1 (MMP1) and decrease of its main inhibitor
tissue inhibitor of metalloproteinase 1 (TIMP1) vs. untreated
HOCl-induced mice, resulting in a favorable MMP1/TIMP1
ratio in tissue (Figure 8F). Of note, untreated mice also
exhibited a significantly higher ratio in comparison with PBS
mice, or SSc mice sacrificed at d42 (data not shown). On
the whole, HOCl discontinuation was responsible for tissue
remodeling activation leading to progressive fibrosis clearance,
a phenomenon significantly improved by MSCs therapy.
DISCUSSION
This study provides original data regarding skin fibrosis
development in a preclinical inducible model for diffuse
SSc. In this murine model, we demonstrated a multi-stage
process leading to skin fibrosis under repeated exposure to
HOCl.
First, during the first 3 weeks of the experiment, daily
injections of HOCl were shown to trigger inflammation and
led to transparietal cellular polymorphous infiltrates, with
high proliferative rate, culminating at d21. These cellular
infiltrates were mostly made of T-lymphocytes and macrophages,
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FIGURE 7 | Anti-fibrotic and anti-inflammatory effects of MSCs treatment on skin fibrosis at day 42. (A) Skin thickness from d21 to d42 in HOCl-SSc mice, HOCl-SSc
mice treated with 2.5 × 105 MSCs at d21 (MSC21), or control PBS mice. N = 8 per group. (B) Representative skin sections at d42 from HOCl-SSc mice and
MSCs-treated HOCl-SSc mice (original magnification 10x; Masson trichrome staining). (C) Collagen content in skin from HOCl-SSc mice and MSCs-treated
HOCl-mice (MSC21). Mean level for control PBS mice are represented by a discontinued line. N = 8 per group. (D) Immunostaining with a-SMA (in red) and TGF-b1
(in green) in skin sections from HOCl-SSc mice (left) and MSCs-treated HOCl-SSc mice (MSC21, right) at d42. (E) Immunostaining with CD3 (in red) and F4/80 (in
green) in skin sections from HOCl-mice (left) and MSC-treated HOCl-mice (MSC21, right) at d42. (F) Quantification of immunostainings in D and E (percentage of
positive cells among all cells observed; n = 4 per group). *P < 0.05, **P < 0.01, ***P < 0.001 vs. HOCl-mice; data are presented as mean ± SEM.
but also myofibroblasts. These observations are consistent
with those made in SSc patients, notably during oedematous
scleroderma, an inflammatory phenotype associated with early
rapidly progressive diffuse SSc, where incisive treatments may be
required (13, 14). In this condition, concordantly with what we
observed, immune cells in skin tissue mainly include CD4+ T-
lymphocytes and macrophages, with sparse B lymphocytes (15,
16). Macrophages are a well-known source of TGFβ secretion,
this soluble mediator being the most critical trigger of fibroblast
activation leading to ECM synthesis (3). Regarding cytokine
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FIGURE 8 | Tissue remodeling after fibrosis induction in HOCl-mice and effects of MSCs treatment at day 63. (A) Evolution of skin thickness after discontinuation of
HOCl challenge in HOCl-induced mice, HOCl-SSc mice treated with 2.5 × 105 at d42 (MSC42), or control PBS mice. (B) Representative skin sections
from HOCl-SSc mice and MSCs-treated HOCl-mice (MSC42) (original magnification 10x, Masson trichrome staining). (C) Immunostaining with a-SMA (in red) and
(Continued)
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FIGURE 8 | TGF-b1 (in green) in skin sections from HOCl-induced mice (left) and MSCs-treated HOCl-induced mice (right). (D) Immunostaining with CD3 (in red) and
F4/80 (in green) in skin sections from HOCl-induced mice (left) and MSCs-treated HOCl-induced mice (right). (E) Quantification of immunostainings in C and D
(percentage of positive cells among all cells observed; n = 4 per group). (F) mRNA expression of cytokines (IL-1b, TNF-a, IL-6, IL-10, left panel) fibrotic markers
(Col-1, Col-3, TGF-b1, a-SMA, middle panel), and remodeling parameters (MMP-1 and TIMP-1, right panel) in skin sections from HOCl-induced mice compared with
HOCl-mice treated with 2.5 × 105 MSCs. Mean levels for control PBS-mice are represented by a discontinued line. *P < 0.05, **P < 0.01, ***P < 0.001 vs.
HOCl-mice; #P < 0.05 vs. PBS-mice; data are presented as mean ± SEM. N = 8 per group.
expression, while IL1β and TNFα are associated with cell-
mediated immunity, IL6 is also known to promote differentiation
of fibroblasts into myofibroblasts (17) and to trigger collagen
production (18). Moreover, at d21, we previously showed in
this model upregulation of pro-inflammatory metalloproteases
(MMP2 and MMP9, also known as gelatinases) and vascular
endothelial growth factor [VEGF; (9)], which may activate
angiogenesis and epithelial/endothelial-mesenchymal transition,
contributing to myofibroblast activation and proliferation (19,
20). On the whole, the primum movens of fibrogenesis in HOCl-
SSc is greatly related to inflammatory activation of skin tissue,
leading to fibroblast proliferation, and preceding ECM synthesis.
In a second phase of HOCl-SSc induction, lasting from
day 21 to day 42, we observed the progressive development
of “matrix fibrosis,” characterized at d42 by paucicellular skin
tissue, with panparietal ECM deposition made of disorganized
collagen fibers. At the end of the 6-wk experiment, skin fibrosis
in SSc mice was characterized by strong ECM deposition made
of disorganized collagen fibers, along with strong thickening
of epidermis and dermis, destructuring all skin layers. This
state of “established fibrosis,” previously described in this model
(9, 12) and responsible for skin thickening and stiffness, is
close to what is usually observed in human SSc. Notably, as
previously reported, tissue remodeling is low at d42, as indicated
by decreased MMP1/TIMP1 ratio in tissue, contributing to
impaired degradation of ECM components (9). Looking at the
immune response, when comparing d42 to d21, we previously
showed less inflammation and proliferation of cells, lower levels
of inflammatory cytokines–except for IL-10 whose level increases
during the 6-wk experiment. Of particular interest, dermal and
hypodermal adipose tissue progressively disappeared during the
whole process, as reported in the bleomycin model (21) and in
human SSc (22), where it has been speculated that adipocyte
attrition could even contribute to fibrogenesis through a putative
adipocyte-to-fibroblast switch under PPAR-γ deregulation (23).
A spontaneous remission of SSc was observed once HOCl
injections ceased, consistent with tissue remodeling activation
and up-regulated MMP1/TIMP1 ratio. This third phase of
fibrogenesis in HOCl-SSc had not been described before, and
represents an original and interesting study model for SSc. As
a matter of fact, clinical evolution in human scleroderma may
be unpredictable, with patients first presenting with early and
rapidly progressive diffuse SSc, but who may secondarily evolve
with spontaneous improvement of skin fibrosis due to natural
remodeling. Hence, this can somehow be disconcerting when
considering therapeutic aspects, notably in the design of clinical
trials (24, 25). Therefore, preclinical models reflecting disease
heterogeneity and mimicking the different stages of fibrosis
development are needed. In that perspective, HOCl-SSc, which
reproduces three distinct phenotypes of scleroderma (i.e., early
inflammatory phase, establishedmatrix fibrosis, and spontaneous
remodeling of tissue), seems particularly helpful to study new
therapeutic approaches.
We previously reported the therapeutic benefits of a single
IV infusion of 2.5 × 105 MSCs, capable of preventing
fibrosis development in a preventive approach, or hampering
fibrosis extension in a curative approach. In the present study,
considering the three steps of fibrosis development and receding
in the model, we focused on the effects obtained 3 weeks after
MSCs infusion (i.e., d21, d42, d63). We demonstrated beneficial
effects of MSCs treatment for each therapeutic strategy, in terms
of skin thickness and histological lesions improvement. However,
benefits were associated with more specific mechanisms. In the
first setting, when infused at d0, MSCs exhibited a pre-eminence
of immunomodulatory properties and were able to efficiently
prevent immune response, resulting in an extinction of cellular
inflammatory infiltrates together with a strong decrease in
cytokine production at d21. These immunomodulatory capacities
of MSCs principally involve paracrine mechanisms with the
secretion of various soluble factors (i.e., IDO, iNOS, PGE2)
down-regulating the immune system (8). In the second setting,
when infused at d21, MSCs treatment was associated with less
myofibroblast activation, and less ECM deposition at d42. These
effects were previously shown to depend primarily on TGFβ
signaling abrogation by MSCs, resulting in lower expression of
TGFβ, TGFβRII and phospho-SMAD in the tissue (9). In the
last setting, when infused at d42, after discontinuation of HOCl
injections, MSCs were shown to enhance tissue remodeling,
leading to enhanced MMP1/TIMP1 ratio and a more rapid
clearance of fibrotic lesions. Interestingly, lost adipose tissue
seemed to be partially restored during the process, suggesting
regenerative potential of MSCs. Of note, MSCs were also able to
prevent autoantibody production when infused at d0, indicating
a specific inhibition of B-cell activation toward plasma cells.
However, we could not observe any effect whenmice were treated
at d21, maybe because of the in vivo half-life of IgG (about 3–4
weeks).
Altogether, we observed benefits of MSCs treatment
whatever the setting of infusion, in three distinct conditions
of fibrosis development, through immunosuppressive, trophic
or regenerative properties. This indicated that not only do
MSCs possess wide and pleiotropic capabilities, but they also
show adaptability and versatility depending on the surrounding
pathological environment. Actually, it has been shown that
according to the signals in the vicinity (hypoxia, ischemia,
cytokine secretion. . . ), MSCs would be primed differently, and
polarized into a specific phenotype [i.e., immunosuppressive,
trophic. . . ; (8, 26)]. This plasticity in response to specific injury
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makes MSCs-based therapy particularly interesting in treating
SSc, considering the heterogeneity of the disease and the
unpredictability of its evolution.
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